Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 04:44:32·⟳ 抓取 04:45:21 +49s·⚡ 决策 08-22 04:52:05 +6m44s·66.8 天前
Cytek在Beckman Coulter专利案中虽胜多数权利要求但被判赔5600万美元
5600万美元判赔约为Cytek 2026年收入指引中点2.095亿美元的27%，也约为近期约6.1亿美元市值的9%，对小市值亏损公司构成可量化法律负担。
📄 原文Investing.com↗ 原文
Cytek Biosciences wins on three of four patent claims
Wall Street posts worst week in over a month amid bond sell-off, rising oil prices FREMONT, Calif. - A jury in the Unit…
不做 Cytek Biosciences（CTKB.US）
事件方向偏空且达到风控风险门槛，但缺少可用实时stock_quote与盘后有效成交价，且公司胜诉多数权利要求并有上诉/审后动议反证，暂不输出可回测SHORT单；禁止新多并等待下个交易日真实开盘定价。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Investing.com在美股收盘后发布Cytek专利案陪审团裁决，称依据公司新闻稿。
关键理由
- 5600万美元判赔约为Cytek 2026年收入指引中点2.095亿美元的27%，也约为近期约6.1亿美元市值的9%，对小市值亏损公司构成可量化法律负担。
- 公司称产品仍可销售且将上诉，减轻了业务中断风险，但不能消除短期现金与估值折价压力。
- 事件发生在美股周五收盘后，若下个交易日开盘大幅跳空，做空边际会迅速被压缩。
主要风险
- Cytek胜诉多数权利要求且仍有审后动议/上诉空间，5600万美元赔偿可能被降低或推迟执行。
- 未能取得事件后实时盘后成交与完整stock_quote报价，无法给出满足执行契约的ENTER价格。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-21 · 影响 weakens
公司称裁决不要求改变现有产品或运营，并将挑战等同侵权及赔偿裁决。
检索:Cytek Biosciences verdict product offerings operations appeal no changes 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
公司二季度现金和有价证券2.62亿美元，短期偿付能力尚可，判赔不是立即流动性危机。
检索:Cytek Biosciences Q2 2026 cash revenue guidance litigation expenses 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-21 · 影响 invalidates
胜诉多数权利要求是正面分项，但新增赔偿义务的净影响仍为负，不支持事件后做多。
检索:Cytek wins three of four patent claims Beckman Coulter damages appeal 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次不升级为可执行SHORT；仅保留风控风险信号和不做新多判断。
方向:未形成可量化同市场高相似先例；方向主要由当前判赔金额相对收入和市值的量级决定。
涨幅量级:未能完成event_study，不能用历史样本校准tp/sl。
形态:无足够样本判断专利判赔类事件是否稳定见光死或连续下跌。
原文全文
展开原文 · 1,863 字
Wall Street posts worst week in over a month amid bond sell-off, rising oil prices
FREMONT, Calif. - A jury in the United States District Court for the District of Delaware returned a verdict today in a patent infringement case brought by Beckman Coulter, Inc. against Cytek Biosciences, Inc. (NASDAQ:CTKB).
The jury found in favor of Cytek on three of the four asserted patent claims, determining noninfringement and invalidity for each of those three claims. On the remaining claim, the jury found no literal infringement but determined infringement under the doctrine of equivalents. The jury awarded damages totaling $56 million, consisting of $20 million in lost profits and $36 million in royalties.
Cytek stated it intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award. The company said the verdict does not require changes to its current product offerings or operations, and its spectral flow cytometry products remain available to customers worldwide.
"We are pleased that the jury found in our favor on the substantial majority of claims in this case," said Dr. Wenbin Jiang, CEO of Cytek Biosciences, according to a press release statement. "We fundamentally disagree with the single remaining finding and damages award and intend to pursue all available post-trial remedies, including potentially an appeal to the United States Court of Appeals for the Federal Circuit."
Cytek is a cell analysis solutions company that develops flow cytometry instruments and related products using its Full Spectrum Profiling technology. The company is headquartered in Fremont, California.
The information is based on a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
FREMONT, Calif. - A jury in the United States District Court for the District of Delaware returned a verdict today in a patent infringement case brought by Beckman Coulter, Inc. against Cytek Biosciences, Inc. (NASDAQ:CTKB).
The jury found in favor of Cytek on three of the four asserted patent claims, determining noninfringement and invalidity for each of those three claims. On the remaining claim, the jury found no literal infringement but determined infringement under the doctrine of equivalents. The jury awarded damages totaling $56 million, consisting of $20 million in lost profits and $36 million in royalties.
Cytek stated it intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award. The company said the verdict does not require changes to its current product offerings or operations, and its spectral flow cytometry products remain available to customers worldwide.
"We are pleased that the jury found in our favor on the substantial majority of claims in this case," said Dr. Wenbin Jiang, CEO of Cytek Biosciences, according to a press release statement. "We fundamentally disagree with the single remaining finding and damages award and intend to pursue all available post-trial remedies, including potentially an appeal to the United States Court of Appeals for the Federal Circuit."
Cytek is a cell analysis solutions company that develops flow cytometry instruments and related products using its Full Spectrum Profiling technology. The company is headquartered in Fremont, California.
The information is based on a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。